Clinical Observation On The Treatment Of Hepatic Fibrosis With Liver Stagnation And Blood Stasis Syndrome By Xianxiao Recipe For Reversing Liver Fibrosis

Objective: To observe the clinical efficacy and safety of the Agreement Prescription of anti-hepatic fibrosis combined with entecavir in the treatment of liver fibrosis in chronic hepatitis B combined with nonalcoholic fatty liver disease.Methods: 54 patients were randomly divided into two groups:control group(n=26)and treatment group(n=28).The control group was treated with entecavir antiviral therapy,and the treatment group was treated with the Agreement Prescription reverse of anti-hepatic fibrosis on the basis of the control group.After 12 weeks of treatment,we compared the changes of TCM syndrome score,LSM,CAP,ALT,AST,GGT and antiviral efficacy between the two groups before and after treatment,and evaluated the therapeutic effect and safety of the combination of the Agreement Prescription of anti-hepatic fibrosis.Results: Before treatment,there was no significant difference in gender,age,TCM syndrome score,LSM,CAP,HBVDNA,ALT,AST and GGT between the two groups(P>0.05).After treatment,the effective rates of TCM syndromes in the treatment group and the control group were 85.71 % and61.54 % respectively,and the comprehensive effective rates of western medicine were 78.57 % and 53.85 % respectively.The effective rates of the two groups were statistically different(P<0.05).After treatment,there were significant differences in TCM syndrome score,LSM,CAP and ALT between the two groups(P<0.05).After treatment,the two groups had no difference in HBVDNA negative conversion rate,antiviral response rate,AST and GGT(P>0.05).Comparing the two groups of patients before and after treatment,the TCM syndrome score,LSM,CAP,HBVDNA negative conversion rate,antiviral response rate,ALT,AST,and GGT results were all statistically significant(P<0.05).During the treatment,there were no adverse reactions in both groups,and there was no obvious abnormality in safety index.Conclusion:1.On the basis of health guidance,the Agreement Prescription of anti-hepatic fibrosis combined with entecavir is effective in the treatment of liver fibrosis patients with liver stagnation and blood stasis syndrome,which had both chronic hepatitis B and non-alcoholic fatty liver disease.Compared with entecavir alone,it can significantly reduce the degree of fibrosis and steatosis,effectively improve clinical symptoms and improve some liver biochemical indexes.2.The Agreement Prescription of anti-hepatic fibrosis can improve the antiviral negative rate and response rate of entecavir,which has a certain positive effect,but it has no obvious advantage over entecavir alone.